Advertisement
Syndax Pharmaceuticals, Inc. (SNDX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
As of 01:36PM EST. Market open.
| Previous Close | 15.83 |
| Open | 16.43 |
| Bid | 16.45 x 100 |
| Ask | 16.62 x 100 |
| Day's Range | 15.73 - 16.90 |
| 52 Week Range | 14.97 - 25.34 |
| Volume | |
| Avg. Volume | 1,180,168 |
| Market Cap | 1.408B |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.64 |
| Earnings Date | Nov 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.36 |
BioPharma DiveSyndax secures FDA OK for new kind of leukemia drug
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain pediatric patients with an aggressive form of acute leukemia.
Pharmaceutical TechnologyFDA approves Syndax’s Revuforj to treat leukaemia
The approval is based on the Phase I/II AUGMENT-101 trial, which included 104 patients with acute leukaemia.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.